ClinicalTrials.gg

Program

Insulin

Also written as “Inhaled Insulin”, “Subcutaneous Insulin” and “Inhaled insulin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Non-alcoholic Fatty Liver Disease · Drug-Related Side Effects and Adverse Reactions, led by 14 companies.

Furthest: phase 4, since Jan 3, 200733 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer110 open or runningphase 4since Jan 3, 2007Aug 22, 2005none ahead
Oramed50 open or runningphase 3since Oct 22, 2020Jun 19, 2013none ahead
Eli Lilly40 open or runningphase 3since Oct 19, 2006Jun 20, 2003none ahead
Oshadi Drug Administration20 open or runningphase 2since Jan 17, 2013Jan 17, 2013none ahead
Sanofi20 open or runningphase 4since Jul 23, 2014Sep 2, 2010none ahead
Baxter Healthcare10 open or runningphase 1since Jul 31, 2006Jul 31, 2006none ahead
cpex-pharmaceuticals-inc10 open or runningphase 2since Feb 23, 2009Feb 23, 2009none ahead
generex-biotechnology-corp10 open or runningphase 3since Apr 24, 2008Apr 24, 2008none ahead
getz-pharma10 open or runningphase 4since Dec 16, 2021Dec 16, 2021none ahead
nastech-pharmaceutical-company-inc10 open or runningphase 2since Feb 7, 2008Feb 7, 2008none ahead
Profil Institut für Stoffwechselforschung10 open or runningphase 1since Sep 14, 2009Sep 14, 2009none ahead
qdose-limited10 open or runningphase 1since Jan 24, 2007Jan 24, 2007none ahead
Roger New10 open or runningphase 2since Jun 19, 2024Jun 19, 2024none ahead
Sam Chun Dang Pharm.11 open or runningphase 1since May 26, 2026May 26, 2026none ahead

Also a collaborator on its studies: integrium, Alkermes, Kowa, nextrials-inc, eresearch-technology-inc, Hoffmann-La Roche, acm-pivotal-global-central-laboratory and Novo Nordisk.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 19 studies since Jun 20, 2003.

  1. Sep 14, 2009Profil Institut für Stoffwechselforschung's first study: phase 1 study in Diabetes Mellitus, Type 2New to Profil Institut für StoffwechselforschungProfil Institut für Stoffwechselforschung · NCT00982254 · 10 enrolled · Germany
  2. Sep 2, 2010Sanofi's first study: phase 3 study in Diabetes Mellitus, Type 1New to SanofiSanofi · NCT01194882 · 479 enrolled · Belgium, France, Netherlands and more
  3. Jan 17, 2013Oshadi Drug Administration's first study: phase 2 study in Diabetes Mellitus, Type 1New to Oshadi Drug AdministrationOshadi Drug Administration · NCT01772251 · 10 enrolled · Israel
  4. Jun 19, 2013Oramed's first study: phase 2 study in Diabetes Mellitus, Type 2New to OramedOramed · NCT01889667 · 30 enrolled · United States
  5. Oct 27, 2013Phase 2 study in Diabetes MellitusOshadi Drug Administration · NCT01973920 · 12 enrolled · Israel
  6. Jul 23, 2014Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT02201004 · 211 enrolled · Japan
  7. Oct 27, 2015Phase 1 study in Diabetes Mellitus, Type 2Eli Lilly · NCT02588950 · 11 enrolled · United States
  8. Dec 24, 2015Phase 2 study in Non-alcoholic Fatty Liver DiseaseOramed · NCT02653300 · 10 enrolled · Israel
  9. Oct 31, 2019Phase 2 study in Diabetes Mellitus, Type 1Oramed · NCT04150107 · 30 enrolled · United States
  10. Oct 22, 2020Phase 3 study in Diabetes Mellitus, Type 2Oramed · NCT04606576 · 710 enrolled · United States
  11. Oct 28, 2020Phase 2 study in Non-alcoholic Fatty Liver DiseaseOramed · NCT04616014 · 7 enrolled · Belgium
  12. Dec 16, 2021getz-pharma's first study: phase 4 study in Drug-Related Side Effects and Adverse ReactionsNew to getz-pharmagetz-pharma · NCT05161741 · 238 enrolled · Pakistan
  13. Jun 19, 2024Roger New's first study: phase 2 study in Type 2 Diabetes Treated With InsulinNew to Roger NewRoger New · NCT06473662 · 153 enrolled · United Kingdom
  14. May 26, 2026Sam Chun Dang Pharm.'s first study: phase 1 study in Diabetes Mellitus, Type 1New to Sam Chun Dang Pharm.Sam Chun Dang Pharm. · NCT07634770 · 16 planned · Germany

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin GlargineruleSanofiphase 4190
Insulin AspartruleNovo Nordiskphase 4146
insulin degludecruleNovo Nordiskphase 4108
insulin glulisineruleSanofiphase 443
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

All 33 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07634770Diabetes Mellitus, Type 1 · Germany1RecruitingSam Chun Dang Pharm.Oct 202616
NCT06473662Type 2 Diabetes Treated With Insulin · United Kingdom2CompletedRoger NewJul 11, 2020153
NCT05161741Drug-Related Side Effects and Adverse Reactions · Pakistan4Completedgetz-pharmaNov 30, 2022238
NCT04616014Non-alcoholic Fatty Liver Disease · Belgium2CompletedOramedJul 1, 20227
NCT04606576Diabetes Mellitus, Type 2 · United States3TerminatedOramedJan 13, 2023710
NCT04150107Diabetes Mellitus, Type 1 · United States2CompletedOramedFeb 6, 202030
NCT02653300Non-alcoholic Fatty Liver Disease · Israel2CompletedOramedMar 1, 202010
NCT02588950Diabetes Mellitus, Type 2 · United States1TerminatedEli LillyMay 25, 201711
NCT02201004Diabetes Mellitus, Type 2 · Japan4CompletedSanofiJan 2016211
NCT01973920Diabetes Mellitus · Israel2CompletedOshadi Drug AdministrationFeb 201712
NCT01889667Diabetes Mellitus, Type 2 · United States2CompletedOramedNov 201330
NCT01772251Diabetes Mellitus, Type 1 · Israel2CompletedOshadi Drug AdministrationJun 201310
NCT01194882Diabetes Mellitus, Type 1 · Belgium, France, Netherlands and more3CompletedSanofiFeb 1, 2018479
NCT00982254Diabetes Mellitus, Type 2 · Germany1CompletedProfil Institut für StoffwechselforschungNov 200110
NCT00850161Diabetes Mellitus, Type 12Withdrawncpex-pharmaceuticals-incAug 20090
NCT00668850Diabetes Mellitus · United States, Bulgaria, Canada and more3UNKNOWNgenerex-biotechnology-corpAug 2011500
NCT00624767Diabetes Mellitus · United States2Completednastech-pharmaceutical-company-incApr 200818
NCT00479258Diabetes Mellitus, Type 1 · United States3TerminatedPfizerOct 20072
NCT00426920Diabetes Mellitus · United States1UNKNOWNqdose-limited14
NCT00418522Diabetes Mellitus, Type 2 · United States, Puerto Rico4CompletedPfizerAug 2008413
NCT00391209Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more3CompletedEli LillyMay 2008379
NCT00358553Healthy · Germany1CompletedBaxter Healthcare
NCT00282971Diabetes Mellitus, Type 2 · Canada, France, Greece and more3TerminatedPfizerFeb 19, 2008354
NCT00150410Diabetes Mellitus · United States, Australia, Brazil and more3CompletedPfizer626
NCT00143338Diabetes Mellitus, Type 2 · United States2CompletedPfizer20
NCT00143104Diabetes Mellitus, Type 1 · United States2CompletedPfizer20
NCT00139659Asthma · United States, Brazil, Canada and more3CompletedPfizerOct 2008288
NCT00138671Diabetes Mellitus · United States, Brazil, Canada and more3TerminatedPfizerSep 2008105
NCT00137046Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more3TerminatedPfizerDec 2008582
NCT00136916Diabetes Mellitus · United States, Brazil, Canada and more3TerminatedPfizerDec 2008635
NCT00134147Diabetes Mellitus · United States, Canada, France and more3CompletedPfizer1,100
NCT00099515Diabetes Mellitus, Type 2 · United States, Argentina, Portugal and more2CompletedEli Lilly97
NCT00063128Diabetes Mellitus, Type 1 · United States2CompletedEli Lilly119

How it is read

Names in the registry

  • “Insulin”, 13 entries
  • “Inhaled Insulin”, 5 entries
  • “Subcutaneous Insulin”, 3 entries
  • “Inhaled insulin”, 3 entries
  • “Inhaled Insulin (Exubera)”, 2 entries

Codes read as this program: LY041001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.